CN110013519A - A kind of pharmaceutical formulation for treating hypertension - Google Patents
A kind of pharmaceutical formulation for treating hypertension Download PDFInfo
- Publication number
- CN110013519A CN110013519A CN201910358825.3A CN201910358825A CN110013519A CN 110013519 A CN110013519 A CN 110013519A CN 201910358825 A CN201910358825 A CN 201910358825A CN 110013519 A CN110013519 A CN 110013519A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- hypertension
- drug
- pharmaceutical formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010020772 Hypertension Diseases 0.000 title claims abstract description 42
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 21
- 239000003814 drug Substances 0.000 claims abstract description 27
- 229940079593 drug Drugs 0.000 claims abstract description 19
- 239000000203 mixture Substances 0.000 claims abstract description 10
- 244000144730 Amygdalus persica Species 0.000 claims abstract description 8
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 8
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 8
- 241001233914 Chelidonium majus Species 0.000 claims abstract description 8
- 239000009636 Huang Qi Substances 0.000 claims abstract description 8
- 235000006040 Prunus persica var persica Nutrition 0.000 claims abstract description 8
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims abstract description 8
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 claims abstract description 8
- 244000292697 Polygonum aviculare Species 0.000 claims abstract description 7
- 235000006386 Polygonum aviculare Nutrition 0.000 claims abstract description 7
- 244000290970 Tetrapanax papyrifer Species 0.000 claims abstract description 7
- 239000002994 raw material Substances 0.000 claims abstract description 4
- 244000228451 Stevia rebaudiana Species 0.000 claims abstract 4
- 238000002360 preparation method Methods 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims 1
- 238000007873 sieving Methods 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 10
- 230000036772 blood pressure Effects 0.000 abstract description 5
- 230000035487 diastolic blood pressure Effects 0.000 abstract description 2
- 206010013663 drug dependence Diseases 0.000 abstract description 2
- 230000007774 longterm Effects 0.000 abstract description 2
- 230000009467 reduction Effects 0.000 abstract description 2
- 208000011117 substance-related disease Diseases 0.000 abstract description 2
- 230000035488 systolic blood pressure Effects 0.000 abstract description 2
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 210000001835 viscera Anatomy 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 241000544066 Stevia Species 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 4
- 230000003276 anti-hypertensive effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 208000001953 Hypotension Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 208000012866 low blood pressure Diseases 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229960003712 propranolol Drugs 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 206010048007 Withdrawal hypertension Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 208000006218 bradycardia Diseases 0.000 description 1
- 230000036471 bradycardia Effects 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 201000005311 drug allergy Diseases 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 201000010849 intracranial embolism Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 229940090007 persantine Drugs 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 208000012201 sexual and gender identity disease Diseases 0.000 description 1
- 208000015891 sexual disease Diseases 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a kind of pharmaceutical formulations for treating hypertension, consist of the following compositions, Radix Angelicae Sinensis, Radix Paeoniae Alba, Rhizoma Chuanxiong, radix rehmanniae preparata, Radix Astragali, safflower, peach kernel, rhizoma polygonati, Fu ox flower, Radix Salviae Miltiorrhizae, paniculate swallowwort, the tuber of multiflower knotweed, the stem pith of the rice-paper plant, stevia rebaudian leaf；It is characterized in that, the pharmaceutical composition of the treatment hypertension includes 5-10 parts of Radix Angelicae Sinensis of parts by weight of raw materials, 10-20 parts of Radix Paeoniae Alba; 2-20 parts of Rhizoma Chuanxiong, 10-15 parts of radix rehmanniae preparata, 6-9 parts of Radix Astragali; 12-15 parts of safflower, 3-6 parts of peach kernel, 6-9 parts of rhizoma polygonati; 2-5 parts of Fu ox flower; 20-30 parts of Radix Salviae Miltiorrhizae, 3-10 parts of paniculate swallowwort, 2-10 parts of the tuber of multiflower knotweed; 3-5 parts of the stem pith of the rice-paper plant, 3-5 parts of stevia rebaudian leaf.The present invention prepares the drug of gained treatment high blood pressure, and blood pressure can be effectively reduced, and systolic pressure is more more obvious than the reduction degree of diastolic pressure, has no toxic side effect, and long-term use will not damage internal organs, and drug dependence is smaller, and medication is safer.
Description
Technical field
The invention belongs to technical field of traditional Chinese medicines, and in particular to a kind of pharmaceutical formulation for treating hypertension.
Background technique
Hypertension is that person in middle and old age's morbidity is more universal in the world, has 5.6 hundred million patients in the world, also has 1.6 hundred million to enter in China,
And be incremented by with annual 3000000 neopathy people, it is one of the problem in the world, not only the death rate is high for it, and it is also very high to make residual rate, when one
Patient is diagnosed as hypertension, he must just go on the road for the pain taken medicine all the life, and it is to bounce that depressor, which is discontinued, now, secondary
Effect is big, long-acting hypotensor, propranolol, is depressured 1-2 weeks and works, and 3-4 weeks just obvious, and side effect is big, and being discontinued can produce
Hypertension rebound, and drowsiness, dizzy, insomnia, low blood pressure bradycardia occur etc.；From quick-acting depressor captoprils are 15 minutes oral
Effect, but 4~6 hours can only be continued, side effect is big, such as low blood pressure, dry cough, allergy, blood vessel and neuronal edema, drug withdrawal blood pressure, that is, anti-
It jumps.There is also the shortcomings that bouncing of being discontinued for the depressor of past simple traditional Chinese medicine.
High blood pressure disease is the disease that person in middle and old age's morbidity is more universal in the world, its cure rate is low, and the death rate is high.For a long time with
To come, treatment hypertension generallys use Western medicine treatment, and such as Western medicine propranolol, this medicine can generate slow, lasting antihypertensive effect,
From medication 1-2 weeks, decompression in 3~4 weeks is obvious, makes to shrink drops 15-20%；But it is small that this medicine of captopril can only continue 4~6
When, it is necessary to take daily, Most patients must lifelong medication, drug withdrawal blood pressure rebound.Application No. is 02159134.2 patents
Application, is a kind of drug for treating cardiovascular and cerebrovascular embolism, can play the role of thrombolysis to heart and brain embolism, it has consciousness regaining,
Heart tonifying is refreshed oneself, and pre- preventing thrombosis generates and the effect of thrombus, it is as the effect that persantine, heart are pacified, both the above medicine
It is the drug for expanding blood vessel that clinic, which is commonly used in treatment angina pectoris, and this drug can expand blood vessel, so it has antihypertensive effect,
Expand blood vessel be temporary, therefore its antihypertensive effect be also it is interim, cannot fundamentally solve.Such as suffer from angina pectoris disease
People, patient can take two vasodilator drugs at once, and the state of an illness is made to be instantly available alleviation equally, also want to thorough coronary heart disease of curing
Do further treatment.Certainly for high blood pressure also there are many Chinese traditional treatment method, human body is divided into as sun by theory of traditional Chinese medical science,
Under as yin, high blood pressure disease is liver-yang hyperactivity, liver wind agitation.High blood pressure disease patient's upper body overabundance of yang, the lower part of the body is empty, with internal
Moisture increases, and blood pressure is stepped up, and patient shows irritability, vexed, dizzy, insomnia, sexual disorder or impotence.Present medication
Mainly diuretic reaches temporary decompression, but Yang Gengsheng with making one in this way, and lower part of the body yin is more empty, makes many patients from the I phase
II or III phase high blood pressure, either western medical treatment or Chinese traditional treatment hypertension are developed to, hypertensive patient must be grown
Phase relies on drug and is treated, and on the one hand prolonged administration of drugs can bring biggish side effect to body, it is more likely that treating
Cause other causes of disease while hypertension.The second is treatment is costly, badly off family is brought mentally and economical
Upper dual-pressure.
Summary of the invention
The purpose of the present invention is to provide a kind of pharmaceutical formulations for treating hypertension, to solve to propose in above-mentioned background technique
The problem of.
To achieve the above object, the invention provides the following technical scheme: a kind of pharmaceutical formulation for treating hypertension, by following
At being grouped as, Radix Angelicae Sinensis, Radix Paeoniae Alba, Rhizoma Chuanxiong, radix rehmanniae preparata, Radix Astragali, safflower, peach kernel, rhizoma polygonati, Fu ox is colored, Radix Salviae Miltiorrhizae, paniculate swallowwort, the tuber of multiflower knotweed, leads to
Grass, stevia rebaudian leaf；The pharmaceutical composition of the treatment hypertension includes 5-10 parts of Radix Angelicae Sinensis of parts by weight of raw materials, and 10-20 parts of Radix Paeoniae Alba,
2-20 parts of Rhizoma Chuanxiong, 10-15 parts of radix rehmanniae preparata, 6-9 parts of Radix Astragali, 12-15 parts of safflower, 3-6 parts of peach kernel, 6-9 parts of rhizoma polygonati, 2-5 parts of Fu ox flower,
20-30 parts of Radix Salviae Miltiorrhizae, 3-10 parts of paniculate swallowwort, 2-10 parts of the tuber of multiflower knotweed, 3-5 parts of the stem pith of the rice-paper plant, 3-5 parts of stevia rebaudian leaf.
Further, each bulk pharmaceutical chemicals are pulverized and sieved, is uniformly mixed by formulation ratio and obtains object treatment hypertension
Pharmaceutical composition.
Further, described pulverize and sieve is to crush to sieve with 100 mesh sieve.
Further, it treats and the tablet of pharmaceutically acceptable auxiliary material preparation is added in the pharmaceutical composition of hypertension, dissipates
Agent, capsule, granule and pill.
Further, application of the pharmaceutical composition of hypertension in preparation treatment hypertension drug is treated.
The present invention prepares the drug of gained treatment high blood pressure, and blood pressure, reduction of the systolic pressure than diastolic pressure can be effectively reduced
Degree is more obvious, has no toxic side effect, and long-term use will not damage internal organs, and drug dependence is smaller, and medication is safer.
Specific embodiment
Below in conjunction with the embodiment of the present invention, technical scheme in the embodiment of the invention is clearly and completely described,
Obviously, described embodiments are only a part of the embodiments of the present invention, instead of all the embodiments.Based in the present invention
Embodiment, every other embodiment obtained by those of ordinary skill in the art without making creative efforts, all
Belong to the scope of protection of the invention.
The present invention provides a kind of pharmaceutical formulation for treating hypertension, consists of the following compositions, Radix Angelicae Sinensis, Radix Paeoniae Alba, and Rhizoma Chuanxiong is ripe
Ground, Radix Astragali, safflower, peach kernel, rhizoma polygonati, Fu ox flower, Radix Salviae Miltiorrhizae, paniculate swallowwort, the tuber of multiflower knotweed, the stem pith of the rice-paper plant, stevia rebaudian leaf；The treatment hypertension
Pharmaceutical composition includes 5-10 parts of Radix Angelicae Sinensis of parts by weight of raw materials, and 10-20 parts of Radix Paeoniae Alba, 2-20 parts of Rhizoma Chuanxiong, 10-15 parts of radix rehmanniae preparata, Radix Astragali
6-9 parts, 12-15 parts of safflower, 3-6 parts of peach kernel, 6-9 parts of rhizoma polygonati, 2-5 parts of Fu ox flower is 20-30 parts of Radix Salviae Miltiorrhizae, 3-10 parts of paniculate swallowwort, first
It is 2-10 parts black, 3-5 parts of the stem pith of the rice-paper plant, 3-5 parts of stevia rebaudian leaf.
Wherein, each bulk pharmaceutical chemicals are pulverized and sieved, is uniformly mixed by formulation ratio and obtains the drug of object treatment hypertension
Composition.
Wherein, described pulverize and sieve is to crush to sieve with 100 mesh sieve.
Wherein, tablet, the powder, glue that pharmaceutically acceptable auxiliary material preparation is added in the pharmaceutical composition of hypertension are treated
Wafer, granule and pill.
This research institute outpatient service hypertensive patient totally 139 are observed, treatment group 80 is randomly divided into, control group 59, treats
Male 38 in group, women 42, the age 30 years old or less 48,30~40 years old 15,41~50 years old 9,51 years old~60 years old 5
Example, 60 years old or more 3.The maximum 71 years old, reckling 11 years old, average age 42 years old High Abnormal Pressure 23, in control group, male 27
Example, women 32,30 years old or less 37,31~40 years old 11,41~50 years old 6,51~60 years old 3,60 years old or more 2.Most
It is person 69 years old, reckling 9 years old, average age 39 years old big.
Wherein, application of the pharmaceutical composition of hypertension in preparation treatment hypertension drug is treated.
Exclusion criteria:
1, carry out that kidney transplant is postoperative and row blood purification treatment person.
2, Pregnant and lactant women.
3, allergic constitution and a variety of drug allergy persons.
4, merge major Liver and hemopoietic system, the severe primaries such as endocrine system disease and mental patient.5, year
Age was in 9 years old or less or 71 years old or more person.
6, not by regulation medication, it can not judge that curative effect or data be not congruent and affect the treatment and safety judgement person.
As a result: effective 12 for the treatment of group, effective 51, invalid 17, treated effect 79%.
Control group effective 3, effective 29, invalid 27, total effective rate 54%.
Treatment group and control group total effective rate statistical procedures have significant difference.
It although an embodiment of the present invention has been shown and described, for the ordinary skill in the art, can be with
A variety of variations, modification, replacement can be carried out to these embodiments without departing from the principles and spirit of the present invention by understanding
And modification, the scope of the present invention is defined by the appended.
Claims (5)
1. a kind of pharmaceutical formulation for treating hypertension, consists of the following compositions, Radix Angelicae Sinensis, Radix Paeoniae Alba, Rhizoma Chuanxiong, radix rehmanniae preparata, Radix Astragali, safflower,
Peach kernel, rhizoma polygonati, Fu ox flower, Radix Salviae Miltiorrhizae, paniculate swallowwort, the tuber of multiflower knotweed, the stem pith of the rice-paper plant, stevia rebaudian leaf；It is characterized in that, the medicine of the treatment hypertension
Compositions include 5-10 parts of Radix Angelicae Sinensis of parts by weight of raw materials, and 10-20 parts of Radix Paeoniae Alba, 2-20 parts of Rhizoma Chuanxiong, 10-15 parts of radix rehmanniae preparata, Radix Astragali 6-9
Part, 12-15 parts of safflower, 3-6 parts of peach kernel, 6-9 parts of rhizoma polygonati, 2-5 parts of Fu ox flower, 20-30 parts of Radix Salviae Miltiorrhizae, 3-10 parts of paniculate swallowwort, the tuber of multiflower knotweed
2-10 parts, 3-5 parts of the stem pith of the rice-paper plant, 3-5 parts of stevia rebaudian leaf.
2. a kind of pharmaceutical formulation for treating hypertension according to claim 1, it is characterised in that: crushed each bulk pharmaceutical chemicals
Sieve is uniformly mixed by formulation ratio and obtains the pharmaceutical composition of object treatment hypertension.
3. a kind of pharmaceutical formulation for treating hypertension according to claim 1, it is characterised in that: described pulverizing and sieving be
Crushing sieves with 100 mesh sieve.
4. a kind of pharmaceutical formulation for treating hypertension according to claim 1, it is characterised in that: treat the drug of hypertension
Tablet, powder, capsule, granule and the pill of pharmaceutically acceptable auxiliary material preparation are added in composition.
5. a kind of pharmaceutical formulation for treating hypertension according to claim 1, it is characterised in that: treat the drug of hypertension
Application of the composition in preparation treatment hypertension drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910358825.3A CN110013519A (en) | 2019-04-22 | 2019-04-22 | A kind of pharmaceutical formulation for treating hypertension |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910358825.3A CN110013519A (en) | 2019-04-22 | 2019-04-22 | A kind of pharmaceutical formulation for treating hypertension |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110013519A true CN110013519A (en) | 2019-07-16 |
Family
ID=67192899
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910358825.3A Pending CN110013519A (en) | 2019-04-22 | 2019-04-22 | A kind of pharmaceutical formulation for treating hypertension |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110013519A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1165626A (en) * | 1997-05-02 | 1997-11-26 | 周连成 | Candy for cardiovascular and cerebrovascular health care |
| CN1593574A (en) * | 2004-07-09 | 2005-03-16 | 贵阳云岩西创药物科技开发有限公司 | Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and its preparing process |
| CN101966253A (en) * | 2010-09-21 | 2011-02-09 | 山东欣博药物研究有限公司 | Tao hong si wu granule and preparation method thereof |
| CN104138424A (en) * | 2014-08-15 | 2014-11-12 | 刘秋莲 | Traditional Chinese medicine composition and preparation method and pharmaceutical use thereof |
| CN106539914A (en) * | 2015-09-21 | 2017-03-29 | 刘永 | A kind of Chinese medicine formula for treating cerebral arteriosclerosis |
| CN108025030A (en) * | 2015-09-14 | 2018-05-11 | 莫里艾克私人有限公司 | It is used to prepare the method for herb extracts |
-
2019
- 2019-04-22 CN CN201910358825.3A patent/CN110013519A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1165626A (en) * | 1997-05-02 | 1997-11-26 | 周连成 | Candy for cardiovascular and cerebrovascular health care |
| CN1593574A (en) * | 2004-07-09 | 2005-03-16 | 贵阳云岩西创药物科技开发有限公司 | Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and its preparing process |
| CN101966253A (en) * | 2010-09-21 | 2011-02-09 | 山东欣博药物研究有限公司 | Tao hong si wu granule and preparation method thereof |
| CN104138424A (en) * | 2014-08-15 | 2014-11-12 | 刘秋莲 | Traditional Chinese medicine composition and preparation method and pharmaceutical use thereof |
| CN108025030A (en) * | 2015-09-14 | 2018-05-11 | 莫里艾克私人有限公司 | It is used to prepare the method for herb extracts |
| CN106539914A (en) * | 2015-09-21 | 2017-03-29 | 刘永 | A kind of Chinese medicine formula for treating cerebral arteriosclerosis |
Non-Patent Citations (2)
| Title |
|---|
| 常复蓉等: "舒冠片的药理研究", 《南京中医药大学学报(自然科学版)》 * |
| 谭晓虹等: "桃红四物汤水提液中没食子酸、芍药苷和红花黄色素含量的测定", 《中成药》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101129817B (en) | Chinese medicine formulation for treating hypertension and method of producing the same | |
| CN107233396B (en) | Traditional Chinese medicine ointment and plaster for treating lumbar disc herniation and preparation method thereof | |
| CN105963411A (en) | Traditional Chinese medicine composition for alleviating asthenopia, preparation of traditional Chinese medicine composition and preparation method thereof | |
| KR100688252B1 (en) | Composition for improving male sexual function | |
| CN110013519A (en) | A kind of pharmaceutical formulation for treating hypertension | |
| CN101284084A (en) | Externally used Chinese medicine for curing hyperosteogeny and protrusion of lumbar intervertebral discs | |
| CN107890528B (en) | Traditional Chinese medicine composition for treating hyperuricemia and preparation method thereof | |
| CN111297997A (en) | Oral Chinese medicinal composition for treating bone diseases and preparation method thereof | |
| KR101840572B1 (en) | Herbal medicine mixed composition for relaxing and curing of climacteric symptom and manufacturing method thereof | |
| CN108404040A (en) | The application of drug containing Turmeric P.E and preparation method thereof and Turmeric P.E in preparing the drug for treatment of arthritis | |
| KR20040094173A (en) | A dry powder of opuntia ficus indica and a composition for removing hangover containing the same | |
| CN101057954B (en) | Traditional Chinese medicine compound for treating transient ischemic attack and its preparation method | |
| CN108938718A (en) | A kind of preparation method of Chinese medicine composition and its preparation for treating headstroke | |
| CN109908246A (en) | The external application Chinese medicine formula for treating lumbar pain orthopaedic disease | |
| CN102743499A (en) | Chinese medicinal herb drug for treating soft tissue internal injury blood stasis and cerebral hemorrhage | |
| CN110575506B (en) | Traditional Chinese medicine composition for treating lumbar disc herniation | |
| KR102320780B1 (en) | Composition for relieving spinal pain and improving spinal flexibility and method for manufacturing the same | |
| CN102512557B (en) | Traditional Chinese medicine for mid-late period recovery from trauma | |
| CN102028919A (en) | Application of Tibetan medicine composition to preparing medicament for treating fracture | |
| CN111701000A (en) | Traditional Chinese medicine preparation for treating thrombus hemiplegia | |
| CN106110228A (en) | A kind of rheumatic hyperosteogeny pain-relieving powder for treating granule and preparation method thereof | |
| CN1234391C (en) | Spine osteopathy liquid | |
| CN111729067A (en) | Acupoint plaster for treating gout and preparation method thereof | |
| CN110664955A (en) | A Chinese medicinal composition for treating lumbar intervertebral disc prolapse, hyperosteogeny and rheumatic arthritis, and its preparation method and application | |
| CN105106378A (en) | Liver clearing and vision improving prescription for treating nyctalopia and preparing method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Lin Guohe Inventor before: Lin Guohua |
|
| CB03 | Change of inventor or designer information | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190716 |
|
| RJ01 | Rejection of invention patent application after publication |